Greenwich LifeSciences (GLSI) Competitors

$24.52 +0.39 (+1.61%)

As of 11:08 AM Eastern

GLSI vs. MPLT, CMPS, JBIO, CALT, and PHAR

Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Maplight Therapeutics (MPLT), Compass Pathways (CMPS), Jade Biosciences (JBIO), Calliditas Therapeutics AB (publ) (CALT), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry.

How does Greenwich LifeSciences compare to Maplight Therapeutics?

Greenwich LifeSciences (NASDAQ:GLSI) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Greenwich LifeSciences currently has a consensus price target of $47.50, indicating a potential upside of 93.74%. Maplight Therapeutics has a consensus price target of $34.43, indicating a potential upside of 19.34%. Given Greenwich LifeSciences' higher probable upside, equities analysts plainly believe Greenwich LifeSciences is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

4.2% of Greenwich LifeSciences shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Maplight Therapeutics had 53 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 56 mentions for Maplight Therapeutics and 3 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.62 beat Maplight Therapeutics' score of 0.46 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	15 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A

Maplight Therapeutics' return on equity of 0.00% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
Maplight Therapeutics	N/A	N/A	N/A

Summary

Maplight Therapeutics beats Greenwich LifeSciences on 7 of the 13 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Compass Pathways?

Greenwich LifeSciences (NASDAQ:GLSI) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Compass Pathways' return on equity of -192.95% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
Compass Pathways	N/A	-192.95%	-61.31%

Greenwich LifeSciences has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market.

Greenwich LifeSciences currently has a consensus price target of $47.50, indicating a potential upside of 93.74%. Compass Pathways has a consensus price target of $20.55, indicating a potential upside of 118.68%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts plainly believe Compass Pathways is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Compass Pathways had 2 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 5 mentions for Compass Pathways and 3 mentions for Greenwich LifeSciences. Compass Pathways' average media sentiment score of 0.78 beat Greenwich LifeSciences' score of 0.62 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.09	N/A

Summary

Compass Pathways beats Greenwich LifeSciences on 11 of the 14 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Jade Biosciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Jade Biosciences had 4 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 7 mentions for Jade Biosciences and 3 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.62 beat Jade Biosciences' score of -0.51 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Greenwich LifeSciences currently has a consensus price target of $47.50, indicating a potential upside of 93.74%. Jade Biosciences has a consensus price target of $34.33, indicating a potential upside of 40.11%. Given Greenwich LifeSciences' higher probable upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Greenwich LifeSciences has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

4.2% of Greenwich LifeSciences shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by insiders. Comparatively, 23.1% of Jade Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Jade Biosciences' return on equity of -51.34% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
Jade Biosciences	N/A	-51.34%	-47.32%

Summary

Jade Biosciences beats Greenwich LifeSciences on 8 of the 14 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Greenwich LifeSciences has a consensus price target of $47.50, indicating a potential upside of 93.74%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Greenwich LifeSciences had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Greenwich LifeSciences and 0 mentions for Calliditas Therapeutics AB (publ). Greenwich LifeSciences' average media sentiment score of 0.62 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Greenwich LifeSciences	Positive

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Greenwich LifeSciences has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A

Greenwich LifeSciences has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Greenwich LifeSciences beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

How does Greenwich LifeSciences compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Pharming Group had 18 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 21 mentions for Pharming Group and 3 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.62 beat Pharming Group's score of 0.24 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group currently has a consensus target price of $38.33, suggesting a potential upside of 193.58%. Greenwich LifeSciences has a consensus target price of $47.50, suggesting a potential upside of 93.74%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts plainly believe Pharming Group is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pharming Group has a net margin of 3.30% compared to Greenwich LifeSciences' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%

Pharming Group has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Pharming Group has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.45	$2.85M	$0.16	81.61
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Pharming Group beats Greenwich LifeSciences on 11 of the 15 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLSI vs. The Competition

Export

Metric	Greenwich LifeSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$336.71M	$3.41B	$6.24B	$12.14B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-16.65	15.32	20.67	25.38
Price / Sales	N/A	304.64	547.41	75.53
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	129.04	6.83	9.59	6.65
Net Income	-$15.79M	$24.11M	$3.54B	$333.19M
7 Day Performance	9.95%	-1.58%	-0.45%	-0.55%
1 Month Performance	-4.90%	3.84%	5.68%	7.66%
1 Year Performance	155.93%	70.95%	38.47%	35.65%

Greenwich LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLSI Greenwich LifeSciences	1.4738 of 5 stars	$24.52 +1.6%	$47.50 +93.7%	+155.9%	$336.71M	N/A	N/A	3	Upcoming Earnings Analyst Upgrade
MPLT Maplight Therapeutics	2.1969 of 5 stars	$28.76 +0.5%	$34.43 +19.7%	N/A	$1.22B	N/A	N/A	109	Insider Trade Gap Down
CMPS Compass Pathways	3.9596 of 5 stars	$9.45 -0.8%	$20.45 +116.5%	+154.6%	$1.22B	N/A	N/A	120	Upcoming Earnings
JBIO Jade Biosciences	2.638 of 5 stars	$24.48 -0.2%	$31.17 +27.3%	N/A	$1.21B	N/A	N/A	20	Earnings Report Analyst Downgrade
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLSI) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. MPLT, CMPS, JBIO, CALT, and PHAR

How does Greenwich LifeSciences compare to Maplight Therapeutics?

Summary

How does Greenwich LifeSciences compare to Compass Pathways?

Summary

How does Greenwich LifeSciences compare to Jade Biosciences?

Summary

How does Greenwich LifeSciences compare to Calliditas Therapeutics AB (publ)?

Summary

How does Greenwich LifeSciences compare to Pharming Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Greenwich LifeSciences (GLSI) Competitors

GLSI vs. MPLT, CMPS, JBIO, CALT, and PHAR

How does Greenwich LifeSciences compare to Maplight Therapeutics?

Do analysts recommend GLSI or MPLT?

Do institutionals and insiders hold more shares of GLSI or MPLT?

Does the media prefer GLSI or MPLT?

Which has better earnings & valuation, GLSI or MPLT?

Is GLSI or MPLT more profitable?

Summary

How does Greenwich LifeSciences compare to Compass Pathways?

Is GLSI or CMPS more profitable?

Which has more volatility & risk, GLSI or CMPS?

Do analysts recommend GLSI or CMPS?

Does the media prefer GLSI or CMPS?

Do institutionals and insiders hold more shares of GLSI or CMPS?

Which has better earnings & valuation, GLSI or CMPS?

Summary

How does Greenwich LifeSciences compare to Jade Biosciences?

Does the media favor GLSI or JBIO?

Which has stronger earnings and valuation, GLSI or JBIO?

Do analysts prefer GLSI or JBIO?

Which has more risk & volatility, GLSI or JBIO?

Do insiders & institutionals hold more shares of GLSI or JBIO?

Is GLSI or JBIO more profitable?

Summary

How does Greenwich LifeSciences compare to Calliditas Therapeutics AB (publ)?

Do analysts rate CALT or GLSI?

Does the media refer more to CALT or GLSI?

Which has more volatility & risk, CALT or GLSI?

Which has preferable valuation and earnings, CALT or GLSI?

Is CALT or GLSI more profitable?

Do institutionals & insiders believe in CALT or GLSI?

Summary

How does Greenwich LifeSciences compare to Pharming Group?

Does the media favor PHAR or GLSI?

Do analysts recommend PHAR or GLSI?

Is PHAR or GLSI more profitable?

Which has more risk & volatility, PHAR or GLSI?

Which has better earnings and valuation, PHAR or GLSI?

Do insiders & institutionals believe in PHAR or GLSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI vs. The Competition

Greenwich LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools